# US 2003/0078375 A1 · High affinity integrin polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0078375 A1
- Document ID: US20030078375A1
- Status: Published application
- Kind: A1
- Application number: 09/805,354
- Filed: 2001-03-13
- Published: 2003-04-24
- Earliest claimed: 2000-07-31
- Assignees: The General Hospital Corporation
- Inventors: M. Amin Arnaout; Rui Li; Jian-Ping Xiong
- Web page: https://patentgrep.com/patent/US20030078375A1

## CPC

- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/70553: {Integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptides comprising all or part of a variant integrin α subunit A domain or a variant integrin β subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the high affinity form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in a lower affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit or any integrin β subunit and could be used therapeutically. The variant integrin polypeptides preferably include a ligand-binding portion of an A-domain or an A-like domain.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding a variant CD11b α subunit having the Ile at position 332 replaced with an amino acid selected from Gly and Ala.

### Claim 2

A isolated nucleic acid molecule encoding a polypeptide consisting of amino acids 144 to 331 of CD11b α subunit.

### Claim 3

An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 144 to 332 of CD11b α subunit wherein the Ile at amino acid 332 has been replaced by an amino acid selected from Gly and Ala.

### Claim 4

A polypeptide comprising amino acids 144 to 332 of CD11b α subunit wherein the Ile at position 332 has been replaced by an amino acid selected from Gly and Ala.

### Claim 5

A polypeptide comprising amino acids 144 to 331 of CD11b α subunit, the polypeptide not comprising amino acids 332 to 1152 of CD11b.

### Claim 6

An isolated nucleic acid molecule encoding a variant CD11a α subunit having the Ile at position 331 replaced with an amino acid selected from Gly and Ala.

### Claim 7

An isolated nucleic acid molecule encoding a polypeptide consisting of amino acids 144 to 330 of CD11a α subunit.

### Claim 8

An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 150 to 331 of CD11a α subunit wherein the Ile at amino acid 331 has been replaced by an amino acid selected from Gly and Ala.

### Claim 9

A polypeptide comprising amino acids 150 to 331 of CD11a α subunit wherein the Ile at position 331 has been replaced by an amino acid selected from Gly and Ala.

### Claim 10

A polypeptide comprising amino acids 150 to 330 of CD11a α subunit, the polypeptide not comprising amino acids 331 to 1223 of CD11a.

### Claim 11

A method for determining whether a test compound is a candidate compound for binding to CD11b, comprising:
(a) contacting a test compound with a polypeptide comprising amino acids 144 to 332 of CD11b α subunit wherein the Ile at amino acid 332 has been replaced by an amino acid selected from Gly and Ala, and
(b) determining whether the test compound binds to the polypeptide,
wherein a compound which binds to the polypeptide is a candidate compound for binding to CD11b.

### Claim 12

A method for determining whether a test compound is a candidate compound for binding to CD11a, comprising:
(a) contacting a test compound with a polypeptide comprising amino acids 150 to 331 of CD11a α subunit wherein the Ile at amino acid 332 has been replaced by an amino acid selected from Gly and Ala, and
(b) determining whether the test compound binds to the polypeptide,
wherein a compound which binds to the polypeptide is a candidate compound for binding to CD11a.
